Identification of protective human monoclonal antibodies for passive immunization against cryptosporidium - cryptosporidiosis is a top ten cause of infant diarrhea in low and middle-income countries…
Active Grant Awarded
- Award ID
- R43AI197630
- Recipient
-
Immport Therapeutics Inc. UEI ZJAMPJY7M149
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $300,000
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 10% complete
- Place of performance
- Irvine, CA 92618, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded Immport Therapeutics Inc., doing business as Antigen Discovery Inc., a grant of $300,000 obligated on September 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds identification of protective human monoclonal antibodies for passive immunization against Cryptosporidium. The source frames the work as an alternative to vaccination, which has no available Cryptosporidium vaccine, for infants in low- and middle-income countries and for elderly Americans with impaired host defenses. The period of performance runs to August 31, 2028, and the place of performance is Irvine, California 92618. The program funds biomedical research and research training in infectious, immunologic, and allergic diseases through grants and cooperative agreements.
Description
Identification of protective human monoclonal antibodies for passive immunization against cryptosporidium - cryptosporidiosis is a top ten cause of infant diarrhea in low and middle-income countries (LMICS), as well as malnutrition and impaired neurocognitive development, leading to substantial yearly morbidity, mortality and lost disability-adjusted life years. A vaccine for cryptosporidiosis is not available that can prevent this disease. During early life, children become infected with cryptosporidium and often do not develop immunity until having repeated infections during subsequent years. This problem is even more pronounced in malnourished children and children under intense pathogen exposure. Recent work by van fossen ET AL. Showed that T follicular helper (TFH) cells, those responsible for supporting B cell responses, become programmed toward an exhaustion-prone phenotype with frequent early pathogen exposure. The broader implications of this are that vaccination, one of the most important and effective tools against infectious diseases, may have diminished effectiveness in the most vulnerable target populations. In addition to children in LMICS, this is a growing concern in the elderly american population, who may be sensitive to cryptosporidiosis due to impaired host defenses. Thus, IT is urgent that we explore alternative approaches to immunization, such as passive transfer of immunity using potent functional monoclonal antibodies (MABS), in order to protect the most vulnerable populations. In a recent phase 1 sbir study, antigen discovery, INC. (ADI) in collaboration with university of virginia (UVA) successfully developed a pan-proteomic cryptosporidium protein microarray that was used to characterize the IGA and IGG antibody responses in children from a high transmission area of bangladesh at one year of life. This study identified cryptosporidial proteins targeted by antibodies and associated with protection from infection and was published by gilchrist and campo ET AL in the J. Clinical investigation. This new sbir phase 1 grant application addresses the urgent need to build on the momentum achieved in our first studies with a new strategy focused on the development of a novel passive immunity vaccine. We hypothesize that antibodies binding with high affinity to target antigens will prevent the adherence and invasion of the parasite into host epithelial cells, resulting in reduced disease severity and the rapid clearance of the parasite. To test this and develop MAB candidates for passive immunization strategies, we will analyze passively transferred maternally-derived antibodies to identify the intersection of passive and adaptive protective antibodies. We will develop a computational workflow utilizing the latest alphafold structural prediction algorithms (currently ALPHAFOLD3) to analyze immunoglobulin variable region sequences and antigen interfaces, i.e., antibody binding epitopes, to identify the best candidate MABS. These MABS will be tested with in vitro functional antibody assays, including invasion neutralization assays and a newly developed inhibition of sporozoite motility assay. A passive immunization strategy for cryptosporidiosis will meet a critical need for protection in early life and among vulnerable populations, and an in silico workflow leveraging constantly evolving structural prediction capabilities will be groundbreaking in the pursuit of vaccines and therapies for many pathogens.
Quick answers
Who received award R43AI197630?
R43AI197630 was awarded to Immport Therapeutics Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 9, 2026.
How much is award R43AI197630 worth?
$300,000 has been obligated on R43AI197630.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award